Purisys Activates Drug Master File for Nalmefene, Introducing New Solution for Acute Opioid Overdose Treatment

Athens, Georgia--(Newsfile Corp. - September 10, 2024) - Purisys LLC, a leading supplier of active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) services, and pharmaceutical reference materials, has submitted its new commercial Drug Master File (DMF) with the US Food and Drug Administration for the active pharmaceutical ingredient nalmefene hydrochloride. The DMF number for nalmefene hydrochloride is 39767 and it is now available for reference, allowing pharmaceutical companies to incorporate Purisys' active pharmaceutical ingredient (API) in their drug development...

2024-09-10 9:00 AM EDT